StudyGraphics #VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma July 23, 2021 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract Using pegylated liposomal doxorubicin as maintenance therapy shows disease improvement in patients with mycosis fungoides #VisualAbstract Indatuximab ravtansine in combination with immunomodulatory drugs shows objective and clinical response in patients with relapsed or refractory multiple myeloma #VisualAbstract: Perioperative oxiplatin with S-1 significantly improves survival in patients with advanced gastric cancer or gastroesophageal adenocarcinoma undergoing D2 gastrectomy
